Analogues of E. coli dihydrofolate reductase (DHFR)
containing modified amino acids at single,
predetermined sites have been prepared. This was accomplished by
the use of the DHFR gene containing an engineered
nonsense codon (TAG) at the positions corresponding to Val-10 and
Asp-27. Misacylated suppressor tRNAs activated
with the modified amino acids of interest were employed for the
suppression of the nonsense codons in a cell free
protein biosynthesizing system, thereby permitting the elaboration of
the desired protein analogues. In this fashion,
the aspartic acid analogues erythro-carboxyproline, cysteic
acid, β,β-dimethylaspartic acid, α-methylaspartic
acid,
erythro- and threo-β-methylaspartic acid,
N-methylaspartic acid, and phosphonoalanine were
incorporated into one
or both of the aformentioned positions. Although a number of these
analogues were incorporated only in low yield,
a modification of the strategy has suggested how this might be improved
significantly. The derived proteins were
purified and then characterized by their mobility on polyacrylamide
gels in comparison with wild-type DHFR.
Representative DHFRs modified at position 10 were also degraded by
defined proteolysis with Glu-C endoproteinase;
the fragments containing the modified amino acids were shown to have
the same chromatographic properties on
reverse phase HPLC as authentic synthetic standards. Individual
analogues were assayed for their abilities to bind
to the substrate analogue methotrexate and to convert dihydrofolate to
tetrahydrofolate. DHFR analogues containing
erythro- and threo-β-methylaspartic acid and
β,β-dimethylaspartic acid were all shown to mediate
tetrahydrofolate
production 74−86% as efficiently as wild-type DHFR under conditions
of multiple substrate turnover. Analysis of
the rates of tetrahydrofolate production in the presence of NADPH and
NADPD at two pH values suggests that this
was due to rate-limiting hydride transfer from NADPH bound to DHFR
analogues whose active site had been altered
structurally.